News of Note—Pfizer, Meridian Medical Technologies, EpiPen, saline shortage

Newspapers

> Pfizer, which previously received a warning letter for the Meridian Medical Technologies plant that makes EpiPen injectors for Mylan, has reported to Health Canada that manufacturing problems have led to a shortage of the 0.3 mg format of the pen which it expects to have resolved by March 2, 2018. Release

> The FDA says that the shortage of saline has now led to a shortage of empty IV bags which healthcare providers have been using for compounded versions of the solution. Release

Sponsored by Lubrizol Life Science

[Webinar] Cannabinoid Formulation - from Farm to Pharma

Wednesday, June 24, 2020 | 12pm ET / 9am PT

A handful of cannabinoid-based pharmaceutical products are on the market today, and an ever-growing number are in the global development pipeline. This webinar will explore key considerations in developing cannabinoid-based pharmaceutical products, including an overview of global pharmaceutical cannabinoid usage today, common challenges formulating with CBD and other cannabinoids, and more.

> Wuhan Chinese Moxibustion Technology Dev. Co., a maker of an updated version of a traditional Chinese medicine, has received an FDA warning letter for GMP failures at its plant in Wuhan, Hubei, China. Letter

Suggested Articles

WuXi AppTec has appointed Celgene CAR-T program veteran David Chang to lead its cell and gene therapy CDMO, WuXi Advanced Therapies.

Maryland-based Emergent BioSolutions has won a $628 million contract with BARDA to manufacture targeted COVID-19 vaccine hopefuls.

A top adviser for the Trump administration is calling on Congress to push for more manufacturing in Puerto Rico.